| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/7/2025 | $31.00 → $78.00 | Neutral → Overweight | Piper Sandler |
| 2/7/2025 | $60.00 → $90.00 | Market Perform → Outperform | Leerink Partners |
| 12/20/2024 | $55.00 | Equal-Weight | Stephens |
| 12/4/2024 | $55.00 | Neutral | Mizuho |
| 11/15/2024 | $58.00 | Neutral | Goldman |
| 11/14/2024 | $33.00 → $53.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/13/2024 | $40.00 → $60.00 | Buy → Hold | Canaccord Genuity |
| 11/8/2024 | $19.00 → $41.00 | Underweight → Equal Weight | Wells Fargo |
| 11/8/2024 | $70.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 10/15/2024 | $35.00 → $52.00 | Equal Weight → Overweight | Barclays |
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G - Doximity, Inc. (0001516513) (Subject)
SC 13G - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
SC 13G/A - Doximity, Inc. (0001516513) (Subject)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
4 - Doximity, Inc. (0001516513) (Issuer)
144 - Doximity, Inc. (0001516513) (Subject)
SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)
SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)
144 - Doximity, Inc. (0001516513) (Subject)
SCHEDULE 13G/A - Doximity, Inc. (0001516513) (Subject)
144 - Doximity, Inc. (0001516513) (Subject)
144 - Doximity, Inc. (0001516513) (Subject)
10-Q - Doximity, Inc. (0001516513) (Filer)
8-K - Doximity, Inc. (0001516513) (Filer)
10-Q - Doximity, Inc. (0001516513) (Filer)
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members
Total revenues of $168.6 million, up 25% year-over-year Net income growth of 57% and adjusted EBITDA growth of 39% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. "We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers." Fiscal 2025 Third Quarter Financial Highlights All com
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2024 after market close on February 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu
Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to help physicians save time, so they can provide better care for their patients." Fiscal 2025 Second Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended September 30, 2023. Revenue:
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members includ
Total revenues of $126.7 million, up 17% year-over-year Net income growth of 46% and adjusted EBITDA growth of 42% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 first quarter ended June 30, 2024. "We were pleased to deliver strong profits and record engagement last quarter, as we beat on both our top and bottom lines," said Jeff Tangney, co-founder and CEO of Doximity. "Last quarter, a record 590,000 unique providers used our AI, telehealth, messaging, and scheduling workflow tools to save time and better serve their patients." Fiscal 2025 First Quarter Financial Highlights All compa
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2024 after market close on August 8, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include mor
Fiscal year 2024 total revenues of $475.4 million, up 13% year-over-year Fiscal year 2024 net income growth of 31% and adjusted EBITDA growth of 25% year-over-year Q4 total revenues of $118.1 million, up 6% year-over-year Q4 net income growth of 32% and adjusted EBITDA growth of 15% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 fourth quarter and fiscal year ended March 31, 2024. "We were pleased to beat on our top and bottom lines, as we delivered another quarter of strong profits and record engagement," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to bring AI and a
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2024 after market close on May 16, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network membe
Total revenues of $135.3 million, up 17% year-over-year Net income margin of 35% and adjusted EBITDA margin of 54% Net income growth of 43% and adjusted EBITDA growth of 32% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 third quarter ended December 31, 2023. "We're proud to deliver another quarter of double-digit engagement growth across our entire platform, with a beat and raise on both our top and bottom lines," said Jeff Tangney, co-founder and CEO of Doximity. "Our clinical workflow tools continue to drive daily use among doctors, and we now count 17 of the top 22 U.S. hospitals as e
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 after market close on May 15, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Anna Bryson, CFO, will present at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025, at 10:25 a.m. Eastern Time/7:25 a.m. Pacific Time. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and rese
Earns A-level ratings in all categories Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named 2025 Best in KLAS in the Video Conferencing Platforms segment. This is the fourth consecutive year that Doximity has earned the top position. In addition to securing the #1 spot, Doximity received A-level ratings in all categories, including operations, product, relationship, value, culture, and loyalty. These ratings, which are based on live interviews with over 80 health system leaders and their staff, reinforce Doximity's leadership in delivering a reliable, easy-to-use virtual care platform. "We're hono
Total revenues of $168.6 million, up 25% year-over-year Net income growth of 57% and adjusted EBITDA growth of 39% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 third quarter ended December 31, 2024. "We're proud to deliver another quarter of record engagement in Q3, with over 610,000 unique providers using our clinical workflow tools," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI tools grew the fastest last quarter, up 60% over the prior quarter, while our newsfeed surpassed more than one million unique providers." Fiscal 2025 Third Quarter Financial Highlights All com
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal third quarter ended December 31, 2024 after market close on February 6, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members inclu
Physicians report telemedicine boosts access, contributes to better disease management, and improves patient outcomes Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician telemedicine users surveyed would like virtual care to remain a permanent part of their clinical practice. Among physicians surveyed, 84% highlighted telemedicine's value in improving continuity of care for patients with chronic or complex conditions, and 96% emphasized its role as a complement to or, depending on the patient, a replacement for in-person care. As part of the study, Doximity analyzed the ad
Total revenues of $136.8 million, up 20% year-over-year Net income growth of 44% and adjusted EBITDA growth of 41% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 second quarter ended September 30, 2024. "Our clinical workflow tools saw record use in Q2 with over 600,000 unique active prescribers," said Jeff Tangney, co-founder and CEO of Doximity. "We're proud to help physicians save time, so they can provide better care for their patients." Fiscal 2025 Second Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended September 30, 2023. Revenue:
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that Nate Gross, co-founder and chief strategy officer, and Anna Bryson, chief financial officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 11:30 a.m. GMT/6:30 a.m. ET. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date w
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2024 after market close on November 7, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members includ
With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati
Piper Sandler upgraded Doximity from Neutral to Overweight and set a new price target of $78.00 from $31.00 previously
Leerink Partners upgraded Doximity from Market Perform to Outperform and set a new price target of $90.00 from $60.00 previously
Stephens initiated coverage of Doximity with a rating of Equal-Weight and set a new price target of $55.00
Mizuho initiated coverage of Doximity with a rating of Neutral and set a new price target of $55.00
Goldman initiated coverage of Doximity with a rating of Neutral and set a new price target of $58.00
Morgan Stanley upgraded Doximity from Underweight to Equal-Weight and set a new price target of $53.00 from $33.00 previously
Canaccord Genuity downgraded Doximity from Buy to Hold and set a new price target of $60.00 from $40.00 previously
KeyBanc Capital Markets upgraded Doximity from Sector Weight to Overweight and set a new price target of $70.00
Wells Fargo upgraded Doximity from Underweight to Equal Weight and set a new price target of $41.00 from $19.00 previously
Barclays upgraded Doximity from Equal Weight to Overweight and set a new price target of $52.00 from $35.00 previously
With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati
Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one